| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 17.8815 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 17.8815. The average price that 007390.KQ shares were previous bought at was KRW 21.5605. The current market price is -17.1% lower than average price they were purchased at. The value of the holding in 007390.KQ has increased by KRW 22,419 compared to the previous valuation of NatureCell Co.,Ltd. however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 28.4986 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 28.4986. The average price that 039200.KQ shares were previous bought at was KRW 20.0221. The current market price is 42.3% higher than average price they were purchased at. The value of the holding in 039200.KQ has fallen by KRW 32,549 compared to the previous valuation of Oscotec Inc. |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 123.354 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 123.354. The average price that 068270.KS shares were previous bought at was KRW 121.344. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in 068270.KS has fallen by KRW 177,341 compared to the previous valuation of CELLTRION INC |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 18.2307 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 18.2307. The average price that 096530.KQ shares were previous bought at was KRW 17.6796. The current market price is 3.1% higher than average price they were purchased at. The value of the holding in 096530.KQ has fallen by KRW 9,258 compared to the previous valuation of Seegene, Inc. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.96761 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.96761. The average price that 13.HK shares were previous bought at was HKD 3.03049. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in 13.HK has fallen by HKD 251 compared to the previous valuation of HUTCHMED (CHINA) LTD |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 4.35632 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 3.23786 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 3.23786. The average price that 1877.HK shares were previous bought at was HKD 2.20212. The current market price is 47.0% higher than average price they were purchased at. The value of the holding in 1877.HK has fallen by HKD 80 compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H |
| 207940.KS - SAMSUNG BIOLOGICS LTD | HOLD | 0 @ KRW 852.862 | KRW 0 | The current share valuation price of 207940.KS based on adjusted close was KRW 852.862. The average price that 207940.KS shares were previous bought at was KRW 720.393. The current market price is 18.4% higher than average price they were purchased at. The value of the holding in 207940.KS has fallen by KRW 86,323 compared to the previous valuation of SAMSUNG BIOLOGICS LTD |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 7.26461 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 7.26461. The average price that 2162.HK shares were previous bought at was HKD 5.23181. The current market price is 38.9% higher than average price they were purchased at. The value of the holding in 2162.HK has fallen by HKD 212 compared to the previous valuation of KEYMED BIOSCIENCES INC |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | HOLD | 0 @ HKD 3.48753 | HKD 0 | The current share valuation price of 2252.HK based on adjusted close was HKD 3.48753. The average price that 2252.HK shares were previous bought at was HKD 3.78461. The current market price is -7.8% lower than average price they were purchased at. The value of the holding in 2252.HK has fallen by HKD 199 compared to the previous valuation of SHANGHAI MICROPORT MEDBOT CLASS H |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 70.4082 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 70.4082. The average price that 237690.KQ shares were previous bought at was KRW 54.2929. The current market price is 29.7% higher than average price they were purchased at. The value of the holding in 237690.KQ has increased by KRW 47,418 compared to the previous valuation of ST Pharm Co.,Ltd. however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 64.96 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 64.96. The average price that 298380.KQ shares were previous bought at was KRW 40.1877. The current market price is 61.6% higher than average price they were purchased at. The value of the holding in 298380.KQ has fallen by KRW 64,624 compared to the previous valuation of ABL Bio Inc. |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 37.1599 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 37.1599. The average price that 302440.KS shares were previous bought at was KRW 36.225. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in 302440.KS has fallen by KRW 22,158 compared to the previous valuation of SK BIOSCIENCE LTD |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 80.0475 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 80.0475. The average price that 326030.KS shares were previous bought at was KRW 73.1926. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in 326030.KS has fallen by KRW 20,729 compared to the previous valuation of SK BIOPHARMACEUTICALS LTD |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 28.2192 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 28.2192. The average price that 328130.KQ shares were previous bought at was KRW 36.9599. The current market price is -23.6% lower than average price they were purchased at. The value of the holding in 328130.KQ has fallen by KRW 5,607 compared to the previous valuation of Lunit Inc. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.63438 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.63438. The average price that 3933.HK shares were previous bought at was HKD 1.74455. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in 3933.HK has fallen by HKD 249 compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 29.8173 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 29.8173. The average price that 4523.T shares were previous bought at was JPY 28.0807. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in 4523.T has fallen by JPY 100,855 compared to the previous valuation of Eisai Co., Ltd. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.3299 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.3299. The average price that 4549.T shares were previous bought at was JPY 13.6521. The current market price is 12.3% higher than average price they were purchased at. The value of the holding in 4549.T has fallen by JPY 9,303 compared to the previous valuation of Eiken Chemical Co., Ltd. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 10.2748 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 10.2748. The average price that 4587.T shares were previous bought at was JPY 11.461. The current market price is -10.3% lower than average price they were purchased at. The value of the holding in 4587.T has fallen by JPY 52,518 compared to the previous valuation of PeptiDream Inc. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 12.0783 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 12.0783. The average price that 4887.T shares were previous bought at was JPY 13.3982. The current market price is -9.9% lower than average price they were purchased at. The value of the holding in 4887.T has fallen by JPY 39,411 compared to the previous valuation of Sawai Group Holdings Co., Ltd. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.97663 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.97663. The average price that 4974.T shares were previous bought at was JPY 5.90785. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in 4974.T has fallen by JPY 15,753 compared to the previous valuation of Takara Bio Inc. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 11.4102 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 11.4102. The average price that 6869.T shares were previous bought at was JPY 17.8798. The current market price is -36.2% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 199,780 compared to the previous valuation of Sysmex Corporation |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 33.8588 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 33.8588. The average price that 6951.T shares were previous bought at was JPY 33.4997. The current market price is 1.1% higher than average price they were purchased at. The value of the holding in 6951.T has fallen by JPY 6,734 compared to the previous valuation of JEOL Ltd. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 9.57051 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 9.57051. The average price that 7575.T shares were previous bought at was JPY 10.3645. The current market price is -7.7% lower than average price they were purchased at. The value of the holding in 7575.T has fallen by JPY 22,242 compared to the previous valuation of Japan Lifeline Co., Ltd. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 27.1318 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 27.1318. The average price that 7701.T shares were previous bought at was JPY 25.4348. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in 7701.T has fallen by JPY 115,078 compared to the previous valuation of Shimadzu Corporation |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 15.6821 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 15.6821. The average price that 7747.T shares were previous bought at was JPY 16.4838. The current market price is -4.9% lower than average price they were purchased at. The value of the holding in 7747.T has fallen by JPY 67,761 compared to the previous valuation of Asahi Intecc Co., Ltd. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 11.2412 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 11.2412. The average price that 9995.HK shares were previous bought at was HKD 9.31045. The current market price is 20.7% higher than average price they were purchased at. The value of the holding in 9995.HK has fallen by HKD 300 compared to the previous valuation of REMEGEN LTD H |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 143.2 | USD 0 | The current share valuation price of A based on adjusted close was USD 143.2. The average price that A shares were previous bought at was USD 118.65. The current market price is 20.7% higher than average price they were purchased at. The value of the holding in A has fallen by USD 329,379 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 225.14 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 225.14. The average price that ABBV shares were previous bought at was USD 191.211. The current market price is 17.7% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 189,706 compared to the previous valuation of AbbVie Inc |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 5.62 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 5.62. The average price that ABCL shares were previous bought at was USD 3.29477. The current market price is 70.6% higher than average price they were purchased at. The value of the holding in ABCL has fallen by USD 2,596 compared to the previous valuation of Abcellera Biologics Inc |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 124.43 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 124.43. The average price that ABT shares were previous bought at was USD 124.109. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in ABT has fallen by USD 243,434 compared to the previous valuation of Abbott Laboratories |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 22.53 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 22.53. The average price that ACAD shares were previous bought at was USD 17.44. The current market price is 29.2% higher than average price they were purchased at. The value of the holding in ACAD has fallen by USD 13,478 compared to the previous valuation of ACADIA Pharmaceuticals Inc |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 86.03 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 86.03. The average price that ACLX shares were previous bought at was USD 63.8126. The current market price is 34.8% higher than average price they were purchased at. The value of the holding in ACLX has fallen by USD 73,820 compared to the previous valuation of Arcellx Inc |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 16.8 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 16.8. The average price that ADPT shares were previous bought at was USD 6.33052. The current market price is 165.4% higher than average price they were purchased at. The value of the holding in ADPT has fallen by USD 18,694 compared to the previous valuation of Adaptive Biotechnologies Corp |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 31.45 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 31.45. The average price that ALKS shares were previous bought at was USD 31.5876. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in ALKS has increased by USD 89,925 compared to the previous valuation of Alkermes Plc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 291.77 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 291.77. The average price that AMGN shares were previous bought at was USD 287.725. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 16,335 compared to the previous valuation of Amgen Inc |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 13.89 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 13.89. The average price that AMLX shares were previous bought at was USD 11.84. The current market price is 17.3% higher than average price they were purchased at. The value of the holding in AMLX has fallen by USD 39,028 compared to the previous valuation of Amylyx Pharmaceuticals Inc |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 36.12 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 36.12. The average price that ANAB shares were previous bought at was USD 22.9035. The current market price is 57.7% higher than average price they were purchased at. The value of the holding in ANAB has fallen by USD 1,058 compared to the previous valuation of AnaptysBio Inc |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 9.43998 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 9.43998. The average price that ARCT shares were previous bought at was USD 16.4363. The current market price is -42.6% lower than average price they were purchased at. The value of the holding in ARCT has fallen by USD 11,749 compared to the previous valuation of Arcturus Therapeutics Holdings Inc |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 9.59 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 9.59. The average price that ARVN shares were previous bought at was USD 11.3332. The current market price is -15.4% lower than average price they were purchased at. The value of the holding in ARVN has increased by USD 7,790 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 33.25 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 33.25. The average price that ASTH shares were previous bought at was USD 27.1156. The current market price is 22.6% higher than average price they were purchased at. The value of the holding in ASTH has fallen by USD 31,747 compared to the previous valuation of Astrana Health Inc |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 35.44 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 35.44. The average price that ATRC shares were previous bought at was USD 33.1524. The current market price is 6.9% higher than average price they were purchased at. The value of the holding in ATRC has fallen by USD 61,343 compared to the previous valuation of AtriCure Inc |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 12.22 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 12.22. The average price that AUPH shares were previous bought at was USD 8.80384. The current market price is 38.8% higher than average price they were purchased at. The value of the holding in AUPH has fallen by USD 66,844 compared to the previous valuation of Aurinia Pharmaceuticals Inc |
| AXGN - Axogen Inc | HOLD | 0 @ USD 22.25 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 22.25. The average price that AXGN shares were previous bought at was USD 16.8496. The current market price is 32.1% higher than average price they were purchased at. The value of the holding in AXGN has increased by USD 225,376 compared to the previous valuation of Axogen Inc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 133.33 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 133.33. The average price that AXSM shares were previous bought at was USD 105.595. The current market price is 26.3% higher than average price they were purchased at. The value of the holding in AXSM has fallen by USD 8,386 compared to the previous valuation of Axsome Therapeutics Inc |
| BANB.SW - | HOLD | 0 @ CHF 73.9461 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 73.9461. The average price that BANB.SW shares were previous bought at was CHF 65.1273. The current market price is 13.5% higher than average price they were purchased at. The value of the holding in BANB.SW has increased by CHF 27,621 compared to the previous valuation of however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 37.5588 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 37.5588. The average price that BAVA.CO shares were previous bought at was DKK 24.9137. The current market price is 50.8% higher than average price they were purchased at. The value of the holding in BAVA.CO has increased by DKK 62,200 compared to the previous valuation of however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.31 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.31. The average price that BCRX shares were previous bought at was USD 7.80196. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 17,673 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 24.77 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 24.77. The average price that BEAM shares were previous bought at was USD 17.8287. The current market price is 38.9% higher than average price they were purchased at. The value of the holding in BEAM has fallen by USD 202,331 compared to the previous valuation of Beam Therapeutics Inc |
| BIIB - Biogen Inc | HOLD | 0 @ USD 147.86 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 147.86. The average price that BIIB shares were previous bought at was USD 128.1. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 140,473 compared to the previous valuation of Biogen Inc |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 130.637 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 130.637. The average price that BIM.PA shares were previous bought at was EUR 119.434. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 92,622 compared to the previous valuation of BioMerieux |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 319.47 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 319.47. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 14.1% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 284,821 compared to the previous valuation of Bio-Rad Laboratories Inc |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 319.47 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 319.47. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 14.1% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 284,821 compared to the previous valuation of Biotest Aktiengesellschaft |
| BIOA-B.ST - | HOLD | 0 @ SEK 31.6371 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 31.6371. The average price that BIOA-B.ST shares were previous bought at was SEK 23.3486. The current market price is 35.5% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has increased by SEK 12,437 compared to the previous valuation of however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 27.54 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 27.54. The average price that BLFS shares were previous bought at was USD 26.74. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in BLFS has fallen by USD 25,362 compared to the previous valuation of BioLife Solutions Inc |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 42.6 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 42.6. The average price that BMY shares were previous bought at was USD 54.5268. The current market price is -21.9% lower than average price they were purchased at. The value of the holding in BMY has fallen by USD 65,991 compared to the previous valuation of Bloomsbury Publishing Plc |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 100.3 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.3. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 3.6% higher than average price they were purchased at. The value of the holding in BSX has fallen by USD 101,003 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 100.3 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.3. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 3.6% higher than average price they were purchased at. The value of the holding in BSX has fallen by USD 101,003 compared to the previous valuation of MULSTRXSSXIMETFP |
| CDNA - Caredx Inc | HOLD | 0 @ USD 14.28 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 14.28. The average price that CDNA shares were previous bought at was USD 19.5286. The current market price is -26.9% lower than average price they were purchased at. The value of the holding in CDNA has fallen by USD 24,674 compared to the previous valuation of Caredx Inc |
| CERT - Certara Inc | HOLD | 0 @ USD 11.58 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 11.58. The average price that CERT shares were previous bought at was USD 10.5583. The current market price is 9.7% higher than average price they were purchased at. The value of the holding in CERT has fallen by USD 78,949 compared to the previous valuation of Certara Inc |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 42.98 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 42.98. The average price that CGON shares were previous bought at was USD 33.16. The current market price is 29.6% higher than average price they were purchased at. The value of the holding in CGON has fallen by USD 54,188 compared to the previous valuation of CG Oncology, Inc. Common stock |
| CHEMM.CO - | HOLD | 0 @ DKK 121.656 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 121.656. The average price that CHEMM.CO shares were previous bought at was DKK 73.2155. The current market price is 66.2% higher than average price they were purchased at. The value of the holding in CHEMM.CO has increased by DKK 112,320 compared to the previous valuation of however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 21.01 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 21.01. The average price that CPRX shares were previous bought at was USD 22.1952. The current market price is -5.3% lower than average price they were purchased at. The value of the holding in CPRX has fallen by USD 51,741 compared to the previous valuation of Catalyst Pharmaceuticals Inc |
| CRL - Creightons Plc | HOLD | 0 @ USD 180.15 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 180.15. The average price that CRL shares were previous bought at was USD 161.828. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in CRL has fallen by USD 467,119 compared to the previous valuation of Creightons Plc |
| CRVL - CorVel Corp | HOLD | 0 @ USD 73.45 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 73.45. The average price that CRVL shares were previous bought at was USD 112.167. The current market price is -34.5% lower than average price they were purchased at. The value of the holding in CRVL has fallen by USD 53,977 compared to the previous valuation of CorVel Corp |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 23.74 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 23.74. The average price that CSTL shares were previous bought at was USD 19.5501. The current market price is 21.4% higher than average price they were purchased at. The value of the holding in CSTL has fallen by USD 14,577 compared to the previous valuation of Castle Biosciences Inc |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 4.01 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 4.01. The average price that CTKB shares were previous bought at was USD 5.75945. The current market price is -30.4% lower than average price they were purchased at. The value of the holding in CTKB has fallen by USD 30,682 compared to the previous valuation of Cytek Biosciences Inc |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 7.04 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 7.04. The average price that DAWN shares were previous bought at was USD 7.37. The current market price is -4.5% lower than average price they were purchased at. The value of the holding in DAWN has fallen by USD 27,206 compared to the previous valuation of Day One Biopharmaceuticals Inc |
| DHR - Danaher Corporation | HOLD | 0 @ USD 214.01 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 214.01. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 8.1% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 213,655 compared to the previous valuation of Danaher Corporation |
| DHR - Danaher Corporation | HOLD | 0 @ USD 214.01 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 214.01. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 8.1% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 213,655 compared to the previous valuation of Danaher Corporation |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 89.1596 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 89.1596. The average price that DIA.MI shares were previous bought at was EUR 51.5128. The current market price is 73.1% higher than average price they were purchased at. The value of the holding in DIA.MI has fallen by EUR 28,484 compared to the previous valuation of DiaSorin SpA |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 10.3 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 10.3. The average price that DVAX shares were previous bought at was USD 12.9918. The current market price is -20.7% lower than average price they were purchased at. The value of the holding in DVAX has fallen by USD 23,286 compared to the previous valuation of Dynavax Technologies Corporation |
| DXCM - DexCom Inc | HOLD | 0 @ USD 68.18 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 68.18. The average price that DXCM shares were previous bought at was USD 79.7195. The current market price is -14.5% lower than average price they were purchased at. The value of the holding in DXCM has fallen by USD 185,580 compared to the previous valuation of DexCom Inc |
| DYVOX.ST - | HOLD | 0 @ SEK 10.7737 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 10.7737. The average price that DYVOX.ST shares were previous bought at was SEK 6.01864. The current market price is 79.0% higher than average price they were purchased at. The value of the holding in DYVOX.ST has fallen by SEK 18,605 compared to the previous valuation of |
| EKTA-B.ST - | HOLD | 0 @ SEK 5.24578 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 5.24578. The average price that EKTA-B.ST shares were previous bought at was SEK 5.55917. The current market price is -5.6% lower than average price they were purchased at. The value of the holding in EKTA-B.ST has increased by SEK 12,118 compared to the previous valuation of however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| EMBC - Embecta Corp | HOLD | 0 @ USD 13.59 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 13.59. The average price that EMBC shares were previous bought at was USD 15.31. The current market price is -11.2% lower than average price they were purchased at. The value of the holding in EMBC has fallen by USD 30,449 compared to the previous valuation of Embecta Corp |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 19.6538 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 19.6538. The average price that EUZ.DE shares were previous bought at was EUR 20.0666. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in EUZ.DE has fallen by EUR 3,215 compared to the previous valuation of Eckert & Ziegler SE |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 7.08 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 7.08. The average price that EVH shares were previous bought at was USD 10.5742. The current market price is -33.0% lower than average price they were purchased at. The value of the holding in EVH has fallen by USD 43,009 compared to the previous valuation of Evolent Health Inc |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 8.33976 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 8.33976. The average price that EVT.DE shares were previous bought at was EUR 6.57563. The current market price is 26.8% higher than average price they were purchased at. The value of the holding in EVT.DE has increased by EUR 17,077 compared to the previous valuation of Evotec SE however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 82.69 | USD 0 | The current share valuation price of EW based on adjusted close was USD 82.69. The average price that EW shares were previous bought at was USD 73.5436. The current market price is 12.4% higher than average price they were purchased at. The value of the holding in EW has increased by USD 98,804 compared to the previous valuation of Edwards Lifesciences Corp however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 62.74 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 62.74. The average price that EXAS shares were previous bought at was USD 51.941. The current market price is 20.8% higher than average price they were purchased at. The value of the holding in EXAS has fallen by USD 128,800 compared to the previous valuation of EXACT Sciences Corporation |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 39.43 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 39.43. The average price that EXEL shares were previous bought at was USD 36.0106. The current market price is 9.5% higher than average price they were purchased at. The value of the holding in EXEL has fallen by USD 214,352 compared to the previous valuation of Exelixis Inc |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 10.44 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 10.44. The average price that FTRE shares were previous bought at was USD 10.2008. The current market price is 2.3% higher than average price they were purchased at. The value of the holding in FTRE has fallen by USD 20,468 compared to the previous valuation of Fortrea Holdings Inc. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 72.27 | USD 0 | The current share valuation price of GH based on adjusted close was USD 72.27. The average price that GH shares were previous bought at was USD 42.8441. The current market price is 68.7% higher than average price they were purchased at. The value of the holding in GH has increased by USD 407,723 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 118.5 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 118.5. The average price that GILD shares were previous bought at was USD 102.696. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 84,353 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 31.5394 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 31.5394. The average price that GLPG.AS shares were previous bought at was EUR 28.0716. The current market price is 12.4% higher than average price they were purchased at. The value of the holding in GLPG.AS has fallen by EUR 5,806 compared to the previous valuation of Galapagos NV |
| GMAB.CO - | HOLD | 0 @ DKK 290.319 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 290.319. The average price that GMAB.CO shares were previous bought at was DKK 214.002. The current market price is 35.7% higher than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 78,084 compared to the previous valuation of |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 23.1991 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 23.1991. The average price that GSK.L shares were previous bought at was GBP 18.3574. The current market price is 26.4% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 1,007,412 compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 65.26 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 65.26. The average price that HALO shares were previous bought at was USD 58.3208. The current market price is 11.9% higher than average price they were purchased at. The value of the holding in HALO has fallen by USD 21,051 compared to the previous valuation of Halozyme Therapeutics Inc |
| HLUN-B.CO - | HOLD | 0 @ DKK 7.39306 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 7.39306. The average price that HLUN-B.CO shares were previous bought at was DKK 5.84339. The current market price is 26.5% higher than average price they were purchased at. The value of the holding in HLUN-B.CO has increased by DKK 51,881 compared to the previous valuation of however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 73.98 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 73.98. The average price that HOLX shares were previous bought at was USD 65.3166. The current market price is 13.3% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 6,898 compared to the previous valuation of Hologic Inc |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 29.32 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 29.32. The average price that HRMY shares were previous bought at was USD 32.4203. The current market price is -9.6% lower than average price they were purchased at. The value of the holding in HRMY has fallen by USD 17,308 compared to the previous valuation of Harmony Biosciences Holdings |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 15.43 | USD 0 | The current share valuation price of IART based on adjusted close was USD 15.43. The average price that IART shares were previous bought at was USD 21.5655. The current market price is -28.5% lower than average price they were purchased at. The value of the holding in IART has fallen by USD 10,751 compared to the previous valuation of Integra LifeSciences Holdings |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.42 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.42. The average price that IBRX shares were previous bought at was USD 2.8497. The current market price is -15.1% lower than average price they were purchased at. The value of the holding in IBRX has fallen by USD 45,138 compared to the previous valuation of Immunitybio Inc |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 32.18 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 32.18. The average price that IDYA shares were previous bought at was USD 21.9973. The current market price is 46.3% higher than average price they were purchased at. The value of the holding in IDYA has fallen by USD 107,213 compared to the previous valuation of Ideaya Biosciences Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 95.03 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 95.03. The average price that ILMN shares were previous bought at was USD 92.7376. The current market price is 2.5% higher than average price they were purchased at. The value of the holding in ILMN has fallen by USD 471,479 compared to the previous valuation of Illumina Inc |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2. The average price that IOVA shares were previous bought at was USD 2.4224. The current market price is -17.4% lower than average price they were purchased at. The value of the holding in IOVA has fallen by USD 64,786 compared to the previous valuation of Iovance Biotherapeutics Inc |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 142.301 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 142.301. The average price that IPN.PA shares were previous bought at was EUR 115.732. The current market price is 23.0% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 132,878 compared to the previous valuation of Ipsen SA however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 217.83 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 217.83. The average price that IQV shares were previous bought at was USD 158. The current market price is 37.9% higher than average price they were purchased at. The value of the holding in IQV has fallen by USD 28,127 compared to the previous valuation of IQVIA Holdings Inc |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 537.59 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 537.59. The average price that ISRG shares were previous bought at was USD 526.895. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in ISRG has fallen by USD 220,896 compared to the previous valuation of Intuitive Surgical Inc |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 27.81 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 27.81. The average price that JANX shares were previous bought at was USD 25.3297. The current market price is 9.8% higher than average price they were purchased at. The value of the holding in JANX has fallen by USD 132,733 compared to the previous valuation of Janux Therapeutics Inc |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 186.6 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 186.6. The average price that JNJ shares were previous bought at was USD 155.455. The current market price is 20.0% higher than average price they were purchased at. The value of the holding in JNJ has fallen by USD 31,598 compared to the previous valuation of Johnson & Johnson |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 37.38 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 37.38. The average price that KNSA shares were previous bought at was USD 37.01. The current market price is 1.0% higher than average price they were purchased at. The value of the holding in KNSA has fallen by USD 105,188 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 10.26 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 10.26. The average price that KURA shares were previous bought at was USD 8.825. The current market price is 16.3% higher than average price they were purchased at. The value of the holding in KURA has fallen by USD 24,071 compared to the previous valuation of Kura Oncology Inc |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.19 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.19. The average price that LAB shares were previous bought at was USD 1.33. The current market price is -10.5% lower than average price they were purchased at. The value of the holding in LAB has fallen by USD 34,052 compared to the previous valuation of Standard Biotools Inc |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 184.52 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 184.52. The average price that LGND shares were previous bought at was USD 112.221. The current market price is 64.4% higher than average price they were purchased at. The value of the holding in LGND has fallen by USD 101,677 compared to the previous valuation of Ligand Pharmaceuticals Incorporated |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 53.34 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 53.34. The average price that LIVN shares were previous bought at was USD 41.8947. The current market price is 27.3% higher than average price they were purchased at. The value of the holding in LIVN has fallen by USD 34,396 compared to the previous valuation of LivaNova PLC |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 55.88 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 55.88. The average price that LNTH shares were previous bought at was USD 85.3876. The current market price is -34.6% lower than average price they were purchased at. The value of the holding in LNTH has fallen by USD 121,691 compared to the previous valuation of Lantheus Holdings Inc |
| LONN.SW - | HOLD | 0 @ CHF 710.687 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 710.687. The average price that LONN.SW shares were previous bought at was CHF 624.949. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in LONN.SW has fallen by CHF 183,330 compared to the previous valuation of |
| MDT - Medtronic PLC | HOLD | 0 @ USD 91.73 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 91.73. The average price that MDT shares were previous bought at was USD 86.0044. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in MDT has fallen by USD 255,567 compared to the previous valuation of Medtronic PLC |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 584.57 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 584.57. The average price that MEDP shares were previous bought at was USD 334.192. The current market price is 74.9% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 118,218 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 85.14 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 85.14. The average price that MMS shares were previous bought at was USD 73.448. The current market price is 15.9% higher than average price they were purchased at. The value of the holding in MMS has fallen by USD 72,617 compared to the previous valuation of LYXETFETUSITETFP |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 86.58 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 86.58. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 82,859 compared to the previous valuation of Marks Electrical Group PLC |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 86.58 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 86.58. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 82,859 compared to the previous valuation of Merck & Company Inc |
| MRNA - Moderna Inc | HOLD | 0 @ USD 24.7 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 24.7. The average price that MRNA shares were previous bought at was USD 26.0014. The current market price is -5.0% lower than average price they were purchased at. The value of the holding in MRNA has fallen by USD 306,748 compared to the previous valuation of Moderna Inc |
| MRUS - Merus BV | HOLD | 0 @ USD 94.81 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 94.81. The average price that MRUS shares were previous bought at was USD 52.0801. The current market price is 82.0% higher than average price they were purchased at. The value of the holding in MRUS has fallen by USD 6,860 compared to the previous valuation of Merus BV |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.07 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.07. The average price that MRVI shares were previous bought at was USD 2.94723. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in MRVI has fallen by USD 25,659 compared to the previous valuation of Maravai Lifesciences Holdings Inc |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 7.91 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 7.91. The average price that MYGN shares were previous bought at was USD 8.86565. The current market price is -10.8% lower than average price they were purchased at. The value of the holding in MYGN has fallen by USD 24,596 compared to the previous valuation of Myriad Genetics Inc |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 138.02 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 138.02. The average price that NBIX shares were previous bought at was USD 124.213. The current market price is 11.1% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 1,123,452 compared to the previous valuation of Neurocrine Biosciences Inc |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 6.23 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 6.23. The average price that NEOG shares were previous bought at was USD 10.6516. The current market price is -41.5% lower than average price they were purchased at. The value of the holding in NEOG has increased by USD 18,513 compared to the previous valuation of Neogen Corporation however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| NEU.AX - | HOLD | 0 @ AUD 14.1893 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 14.1893. The average price that NEU.AX shares were previous bought at was AUD 6.49393. The current market price is 118.5% higher than average price they were purchased at. The value of the holding in NEU.AX has increased by AUD 15,482 compared to the previous valuation of however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 123.767 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 123.767. The average price that NOVN.SW shares were previous bought at was CHF 105.855. The current market price is 16.9% higher than average price they were purchased at. The value of the holding in NOVN.SW has fallen by CHF 119,961 compared to the previous valuation of |
| NTRA - Natera Inc | HOLD | 0 @ USD 192.81 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 192.81. The average price that NTRA shares were previous bought at was USD 159.203. The current market price is 21.1% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 293,655 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| NUVB - Nuvation Bio Inc | HOLD | 0 @ USD 5.26 | USD 0 | The current share valuation price of NUVB based on adjusted close was USD 5.26. The average price that NUVB shares were previous bought at was USD 3.35. The current market price is 57.0% higher than average price they were purchased at. The value of the holding in NUVB has fallen by USD 32,915 compared to the previous valuation of Nuvation Bio Inc |
| NVAX - Novavax Inc | HOLD | 0 @ USD 8.38 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 8.38. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 28.4% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 25,979 compared to the previous valuation of Novavax Inc |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 8.38 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 8.38. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 28.4% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 25,979 compared to the previous valuation of Hana Microelectronics Public Company Limited |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 13.48 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 13.48. The average price that NVCR shares were previous bought at was USD 23.2352. The current market price is -42.0% lower than average price they were purchased at. The value of the holding in NVCR has increased by USD 13,470 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.82997 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.82997. The average price that ONT.L shares were previous bought at was GBP 1.69938. The current market price is 7.7% higher than average price they were purchased at. The value of the holding in ONT.L has increased by GBP 29,256 compared to the previous valuation of Oxford Nanopore Technologies Ltd however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 2.01 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 2.01. The average price that PACB shares were previous bought at was USD 1.30688. The current market price is 53.8% higher than average price they were purchased at. The value of the holding in PACB has increased by USD 14,844 compared to the previous valuation of Pacific Biosciences of California however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 24.29 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 24.29. The average price that PFE shares were previous bought at was USD 24.2467. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in PFE has fallen by USD 129,513 compared to the previous valuation of Pfizer Inc |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.33669 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.33669. The average price that PHARM.AS shares were previous bought at was EUR 0.824707. The current market price is 62.1% higher than average price they were purchased at. The value of the holding in PHARM.AS has fallen by EUR 2,454 compared to the previous valuation of Pharming Group NV |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 85.847 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 85.847. The average price that PHM.MC shares were previous bought at was EUR 87.6333. The current market price is -2.0% lower than average price they were purchased at. The value of the holding in PHM.MC has fallen by EUR 1,272 compared to the previous valuation of Pharma Mar SA |
| PINC - Premier Inc | HOLD | 0 @ USD 28.11 | USD 0 | The current share valuation price of PINC based on adjusted close was USD 28.11. The average price that PINC shares were previous bought at was USD 26.81. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in PINC has fallen by USD 6,986 compared to the previous valuation of Premier Inc |
| PME.AX - | HOLD | 0 @ AUD 178.068 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 178.068. The average price that PME.AX shares were previous bought at was AUD 163.975. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 503,388 compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 316.17 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 316.17. The average price that PODD shares were previous bought at was USD 275.459. The current market price is 14.8% higher than average price they were purchased at. The value of the holding in PODD has fallen by USD 409,611 compared to the previous valuation of Insulet Corporation |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 195.76 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 195.76. The average price that PRAX shares were previous bought at was USD 39.42. The current market price is 396.6% higher than average price they were purchased at. The value of the holding in PRAX has fallen by USD 88,133 compared to the previous valuation of Praxis Precision Medicines Inc |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 67.35 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 67.35. The average price that PTCT shares were previous bought at was USD 49.1674. The current market price is 37.0% higher than average price they were purchased at. The value of the holding in PTCT has fallen by USD 13,450 compared to the previous valuation of PTC Therapeutics Inc |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 27.94 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 27.94. The average price that QDEL shares were previous bought at was USD 29.6453. The current market price is -5.8% lower than average price they were purchased at. The value of the holding in QDEL has fallen by USD 20,492 compared to the previous valuation of Quidel Corporation |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 47.7991 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 47.7991. The average price that QIA.DE shares were previous bought at was EUR 40.6149. The current market price is 17.7% higher than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 43,277 compared to the previous valuation of QIAGEN NV |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 20.29 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 20.29. The average price that RCUS shares were previous bought at was USD 8.69153. The current market price is 133.4% higher than average price they were purchased at. The value of the holding in RCUS has increased by USD 36,990 compared to the previous valuation of Arcus Biosciences Inc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 148.48 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 148.48. The average price that RGEN shares were previous bought at was USD 136.541. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in RGEN has fallen by USD 197,476 compared to the previous valuation of Repligen Corporation |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 12.84 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 12.84. The average price that RGNX shares were previous bought at was USD 8.37881. The current market price is 53.2% higher than average price they were purchased at. The value of the holding in RGNX has fallen by USD 17,460 compared to the previous valuation of Regenxbio Inc |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 7.31 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 7.31. The average price that RLAY shares were previous bought at was USD 3.79905. The current market price is 92.4% higher than average price they were purchased at. The value of the holding in RLAY has fallen by USD 36,376 compared to the previous valuation of Relay Therapeutics Inc |
| RO.SW - | HOLD | 0 @ CHF 342.778 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 342.778. The average price that RO.SW shares were previous bought at was CHF 367.716. The current market price is -6.8% lower than average price they were purchased at. The value of the holding in RO.SW has fallen by CHF 4,253 compared to the previous valuation of |
| ROG.SW - | HOLD | 0 @ CHF 327.197 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 327.197. The average price that ROG.SW shares were previous bought at was CHF 304.279. The current market price is 7.5% higher than average price they were purchased at. The value of the holding in ROG.SW has fallen by CHF 94,522 compared to the previous valuation of |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 95.3 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 95.3. The average price that RVTY shares were previous bought at was USD 87.5022. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in RVTY has fallen by USD 165,173 compared to the previous valuation of Revvity Inc. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 5.87 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 5.87. The average price that RXRX shares were previous bought at was USD 5.16079. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in RXRX has fallen by USD 19,378 compared to the previous valuation of Recursion Pharmaceuticals Inc |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 113.89 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 113.89. The average price that RYTM shares were previous bought at was USD 64.092. The current market price is 77.7% higher than average price they were purchased at. The value of the holding in RYTM has increased by USD 30,602 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 21.15 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 21.15. The average price that SDGR shares were previous bought at was USD 23.4925. The current market price is -10.0% lower than average price they were purchased at. The value of the holding in SDGR has fallen by USD 44,093 compared to the previous valuation of Schrodinger Inc |
| SECT-B.ST - | HOLD | 0 @ SEK 32.9838 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 32.9838. The average price that SECT-B.ST shares were previous bought at was SEK 27.1554. The current market price is 21.5% higher than average price they were purchased at. The value of the holding in SECT-B.ST has increased by SEK 19,928 compared to the previous valuation of however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| SFZN.SW - | HOLD | 0 @ CHF 99.1393 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 99.1393. The average price that SFZN.SW shares were previous bought at was CHF 124.687. The current market price is -20.5% lower than average price they were purchased at. The value of the holding in SFZN.SW has fallen by CHF 446 compared to the previous valuation of |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 17.79 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 17.79. The average price that SLP shares were previous bought at was USD 26.7306. The current market price is -33.4% lower than average price they were purchased at. The value of the holding in SLP has fallen by USD 9,645 compared to the previous valuation of Sylvania Platinum Limited |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 23.45 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 23.45. The average price that SRPT shares were previous bought at was USD 57.6553. The current market price is -59.3% lower than average price they were purchased at. The value of the holding in SRPT has fallen by USD 91,724 compared to the previous valuation of Sarepta Therapeutics Inc |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 279.703 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 279.703. The average price that SRT3.DE shares were previous bought at was EUR 226.06. The current market price is 23.7% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 128,772 compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 31.41 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 31.41. The average price that STOK shares were previous bought at was USD 11.6276. The current market price is 170.1% higher than average price they were purchased at. The value of the holding in STOK has fallen by USD 14,554 compared to the previous valuation of Stoke Therapeutics Inc |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 55.68 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 55.68. The average price that SUPN shares were previous bought at was USD 34.9586. The current market price is 59.3% higher than average price they were purchased at. The value of the holding in SUPN has increased by USD 171,880 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| SXS.L - Spectris PLC | HOLD | 0 @ GBP 54.3696 | GBP 0 | The current share valuation price of SXS.L based on adjusted close was GBP 54.3696. The average price that SXS.L shares were previous bought at was GBP 55.4271. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in SXS.L has fallen by GBP 11,392 compared to the previous valuation of Spectris PLC |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 62.02 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 62.02. The average price that TECH shares were previous bought at was USD 58.2868. The current market price is 6.4% higher than average price they were purchased at. The value of the holding in TECH has fallen by USD 367,728 compared to the previous valuation of Bio-Techne Corp |
| TECN.SW - | HOLD | 0 @ CHF 187.096 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 187.096. The average price that TECN.SW shares were previous bought at was CHF 202.814. The current market price is -7.7% lower than average price they were purchased at. The value of the holding in TECN.SW has increased by CHF 20,284 compared to the previous valuation of however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 33.78 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 33.78. The average price that TGTX shares were previous bought at was USD 34.3438. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in TGTX has fallen by USD 133,955 compared to the previous valuation of TG Therapeutics Inc |
| TMO - Time Out Group plc | HOLD | 0 @ USD 558.31 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 558.31. The average price that TMO shares were previous bought at was USD 407.896. The current market price is 36.9% higher than average price they were purchased at. The value of the holding in TMO has increased by USD 24,574 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 15.15 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 15.15. The average price that TNDM shares were previous bought at was USD 22.0991. The current market price is -31.4% lower than average price they were purchased at. The value of the holding in TNDM has increased by USD 4,015 compared to the previous valuation of Tandem Diabetes Care Inc however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 32.21 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 32.21. The average price that TWST shares were previous bought at was USD 42.9063. The current market price is -24.9% lower than average price they were purchased at. The value of the holding in TWST has fallen by USD 90,486 compared to the previous valuation of Twist Bioscience Corp |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 12.9 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 12.9. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 7.7% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 59,242 compared to the previous valuation of 10X Genomics Inc |
| TXG - Terex Corporation | HOLD | 0 @ USD 12.9 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 12.9. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 7.7% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 59,242 compared to the previous valuation of Terex Corporation |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 274.454 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 274.454. The average price that UCB.BR shares were previous bought at was EUR 188.363. The current market price is 45.7% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 761,880 compared to the previous valuation of UCB SA however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 35.41 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 35.41. The average price that VCYT shares were previous bought at was USD 31.3293. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in VCYT has fallen by USD 17,187 compared to the previous valuation of Veracyte Inc |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.91 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.91. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -26.5% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 64,958 compared to the previous valuation of Vir Biotechnology Inc |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.91 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.91. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -26.5% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 64,958 compared to the previous valuation of Vidrala S.A |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.61661 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.61661. The average price that VLA.PA shares were previous bought at was EUR 2.86092. The current market price is 61.4% higher than average price they were purchased at. The value of the holding in VLA.PA has increased by EUR 11,742 compared to the previous valuation of Valneva SE however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 5.41 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 5.41. The average price that VNDA shares were previous bought at was USD 4.49047. The current market price is 20.5% higher than average price they were purchased at. The value of the holding in VNDA has fallen by USD 11,749 compared to the previous valuation of Vanda Pharmaceuticals Inc |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 23.01 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 23.01. The average price that VRDN shares were previous bought at was USD 19.65. The current market price is 17.1% higher than average price they were purchased at. The value of the holding in VRDN has fallen by USD 15,968 compared to the previous valuation of Viridian Therapeutics Inc |
| XVIVO.ST - | HOLD | 0 @ SEK 20.4465 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 20.4465. The average price that XVIVO.ST shares were previous bought at was SEK 42.7002. The current market price is -52.1% lower than average price they were purchased at. The value of the holding in XVIVO.ST has increased by SEK 13,302 compared to the previous valuation of however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 19.38 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 19.38. The average price that ZYME shares were previous bought at was USD 14.3. The current market price is 35.5% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 5,024 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |